A Smarter Exit for Stranded Biotech
Alis Biosciences is a London-based investment fund launched in April 2025 to address the issue of approximately $30 billion in capital trapped within nearly 300 publicly listed, development-stage biotech companies that have encountered clinical, regulatory, or commercial setbacks. These companies often possess significant cash reserves but face challenges in progressing their programs, leading to diminished shareholder value and limited options for capital recovery. Alis offers innovative exit strategies by acquiring such companies, delisting them, and returning the majority of uncommitted cash to shareholders. This approach provides an alternative to traditional exits like reverse mergers or liquidations, which can be time-consuming and costly. Additionally, Alis aims to preserve and potentially develop residual science and intellectual property through specialized structures, thereby unlocking value for stakeholders. 2 June 2025
From Wall Street to Financial Impact
Curt Bassett is an investment professional with over 30 years of experience spanning financial planning, investment consulting, Wall Street leadership, and advisory roles within Family Offices and Family Foundations. Drawing on his extensive background, Curt emphasizes the importance of Impact Investing as a tool to break the common three-generation cycle of wealth—where the first generation creates it, the second enjoys it, and the third depletes it. His book, The Third Impact, offers a strategic framework to preserve wealth and purpose across generations, serving as a powerful antidote to “affluenza”. - 30 May 2025.
PURCHASE BOOK ->
Scientific Rigor Meets Startup Execution
Dr. Tristan G Heintz is a scientist-turned-founder who advises early-stage biotech teams on translating ideas into therapies, from refining scientific hypotheses to designing credible, fundable development plans. With hands-on experience in in vivo validation, early-stage fundraising, and a broad CRO network across biology and chemistry, he brings both scientific depth and startup pragmatism to support lean, high-impact execution. He is especially passionate about helping mission-driven ventures build a clear scientific narrative that resonates with both investors and partners. - 29 May 2025.
Crystallography in the Age of AI: The Future of Structural Biology
In this conversation, we sit down with Dr. Ryan Jackson, a leading structural biologist and faculty member at Utah State University, to explore the enduring relevance of X-ray crystallography in an era dominated by cryo-EM and AI-powered protein prediction tools like AlphaFold. Dr. Jackson shares his expert insights on when and why crystallography is still the gold standard for resolving novel protein structures, how it compares to newer technologies, and why young scientists should continue to value and learn this foundational technique. - 23 May 2025.
The Importance of IP in Biotech Portfolios
Danny Barber, IP Attorney, emphasizes the importance of building a strategic intellectual property (IP) portfolio to help startups secure funding and successfully bring products to market. He notes, it not uncommon for those involved in early-stage drug discovery to often lack sufficient knowledge of IP, which can hinder long-term success. Investors view IP as a critical factor — one of the most valuable assets a startup can leverage when seeking funding. - 29 April 2025.
Capital, Care, and Courage: The Future of Health Innovation
In a powerful session hosted by Dr. Joseph Nowoslawski, Jolene Anderson and Mike Russell shared hard-won insights from decades of building and advising companies across life sciences, medtech, and cleantech. Jolene, a strategic advisor and fund co-founder, spoke to financing and sustainability, while Mike, a former medtech executive turned startup leader, highlighted lessons in scaling, capital, and exits. Together, they offered practical guidance for founders navigating early-stage growth. - 11 April 2025
Innovation Awards
Dr. Joseph Nowoslawski highlights how outdated 1938 regulations stifle biotech innovation, preventing 90% of discoveries from reaching patients despite billions spent on research and development. He emphasizes the need for regulatory modernization through the FDA Modernization Act 2.0, advocating for new technologies and funding support to help biotech startups. - 8 January 2024
UHE Webinar Dec 23
We hosted a webinar for Utah Health Entrepreneurs, bringing together industry professionals to explore opportunities and address inefficiencies in the biotech and life sciences sectors. We hosted Dr. D’vorah Graeser, Founder & CEO | RocketSmart and KISSPatent and Michael Savvides CEO & Co-founder at Imagine Biotech.
- 23 December 2024
UHE Webinar Oct 24
On Monday, October 21, 2024, we hosted a webinar for Utah Health Entrepreneurs, bringing together industry professionals to explore opportunities and address inefficiencies in the biotech and life sciences sectors. A key theme was the shift towards alternative methods to traditional animal trials when conducting scientific due diligence, an approach increasingly encouraged to become an industry standard in the development of drug therapeutics and technologies.